Businello G , Angerilli V , Lonardi S , Bergamo F , Valmasoni M , Farinati F , Savarino E , Spolverato G , Fassan M .

22759 Associazione Italiana per la Ricerca sul Cancro, NET-2016-02363853 Regione del Veneto

Ahn, High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. 2017, Pubmed

Ahn, High-throughput Protein and mRNA Expression-based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. 2017, Pubmed
Alexandrov, A mutational signature in gastric cancer suggests therapeutic strategies. 2015, Pubmed
Anderson, Age-specific trends in incidence of noncardia gastric cancer in US adults. 2010, Pubmed
Angerilli, Epstein-Barr virus associated gastric dysplasia: a new rare entity? 2022, Pubmed
Attia, Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy. 2021, Pubmed
Bang, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. 2010, Pubmed
Bang, Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. 2015, Pubmed
Bang, Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. 2017, Pubmed
Bartley, HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. 2017, Pubmed
Bozzetti, Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. 2011, Pubmed
Businello, Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. 2021, Pubmed
Businello, The impact of recent next generation sequencing and the need for a new classification in gastric cancer. 2021, Pubmed
Cancer Genome Atlas Research Network, Comprehensive molecular characterization of gastric adenocarcinoma. 2014, Pubmed
Cancer Genome Atlas Research Network, Integrated genomic characterization of oesophageal carcinoma. 2017, Pubmed
Cappellesso, HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. 2015, Pubmed
Catenacci, Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. 2020, Pubmed
Catenacci, MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. 2021, Pubmed
Catenacci, Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. 2019, Pubmed
Catenacci, Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. 2017, Pubmed
Chen, Prognostic value of matrix metalloproteinase-9 in gastric cancer: a meta-analysis. 2014, Pubmed
Cho, Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. 2013, Pubmed
Coati, Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. 2019, Pubmed
Cristescu, Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. 2015, Pubmed
Doi, Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. 2017, Pubmed
Fassan, Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. 2020, Pubmed
Fassan, Early HER2 dysregulation in gastric and oesophageal carcinogenesis. 2012, Pubmed
Fassan, Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. 2012, Pubmed
Fassan, PD-L1 expression in gastroesophageal dysplastic lesions. 2020, Pubmed
Frigault, Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer. 2020, Pubmed
Fuchs, Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. 2018, Pubmed
Fuchs, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. 2014, Pubmed
Fukuoka, Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). 2020, Pubmed
Fusco, HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. 2013, Pubmed
Gall, Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. 2017, Pubmed
Golan, Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. 2019, Pubmed
Greally, Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. 2019, Pubmed
Gullo, Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. 2020, Pubmed
Gullo, Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. 2015, Pubmed
Gylling, Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. 2007, Pubmed
Iwata, [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. 2019, Pubmed
Janjigian, Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. 2018, Pubmed
Janjigian, The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. 2021, Pubmed
Jiang, Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. 2019, Pubmed
Kaito, HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. 2019, Pubmed
Kang, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. 2017, Pubmed
Kawazoe, Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. 2020, Pubmed
Kawazoe, Next-generation sequencing and biomarkers for gastric cancer: what is the future? 2019, Pubmed
Kim, Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. 2011, Pubmed
Kim, Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. 2018, Pubmed
Kim, Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. 2018, Pubmed
Kotani, Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. 2021, Pubmed
Ku, Next generation sequencing in gastric or gastroesophageal adenocarcinoma. 2020, Pubmed
Kulukian, Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. 2020, Pubmed
LAUREN, THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. 1965, Pubmed
Le, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. 2015, Pubmed
Li, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. 2016, Pubmed
Liao, Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma. 2018, Pubmed
Lordick, Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. 2013, Pubmed
Marabelle, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. 2020, Pubmed
Maron, Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. 2018, Pubmed
Marx, HER-2 amplification is highly homogenous in gastric cancer. 2009, Pubmed
Matsumoto, FGFR2 gene amplification and clinicopathological features in gastric cancer. 2012, Pubmed
Ménard, Biologic and therapeutic role of HER2 in cancer. 2003, Pubmed
Nagatsuma, Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. 2015, Pubmed
Nakamura, SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors. 2021, Pubmed
Nakamura, Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. 2021, Pubmed
Nakamura, Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. 2020, Pubmed
Nakayama, Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults. 2019, Pubmed
Oga, Genomic profiles of colorectal carcinoma with liver metastases and newly identified fusion genes. 2019, Pubmed
Ohtsu, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. 2011, Pubmed
Parikh, Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. 2019, Pubmed
Park, Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). 2016, Pubmed
Pavlakis, Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. 2016, Pubmed
Pectasides, Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. 2018, Pubmed
Pellino, Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. 2019, Pubmed
Pellino, Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. 2021, Pubmed
Petty, Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. 2017, Pubmed
Pietrantonio, Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. 2018, Pubmed
Pietrantonio, HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. 2016, Pubmed
Pietrantonio, Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. 2021, Pubmed
Pu, Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA. 2016, Pubmed
Rubenstein, Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. 2010, Pubmed
Sahin, A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. 2018, Pubmed
Sahin, FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. 2021, Pubmed
Seo, Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). 2019, Pubmed
Shah, Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. 2017, Pubmed
Shah, Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. 2018, Pubmed
Shah, Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). 2021, Pubmed
Shen, Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). 2015, Pubmed
Shitara, Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. 2020, Pubmed
Shitara, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. 2018, Pubmed
Shitara, Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. 2020, Pubmed
Shitara, Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer. 2017, Pubmed
Singh, Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. 2017, Pubmed
Smyth, Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. 2017, Pubmed
Smyth, EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. 2021, Pubmed
Stagg, Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. 2011, Pubmed
Su, FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. 2014, Pubmed
Sung, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021, Pubmed
Thangaraju, Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors. 2015, Pubmed
Türeci, A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. 2019, Pubmed
Van Cutsem, HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. 2015, Pubmed
Van Cutsem, A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. 2017, Pubmed
Velho, Causes and consequences of microsatellite instability in gastric carcinogenesis. 2014, Pubmed
Wakatsuki, Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. 2018, Pubmed
Wilke, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. 2014, Pubmed
Xie, FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. 2013, Pubmed
Yagi, Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. 2019, Pubmed